Boussard & Gavaudan Investment Management LLP Sage Therapeutics, Inc. Transaction History
Boussard & Gavaudan Investment Management LLP
- $102 Million
- Q2 2025
A detailed history of Boussard & Gavaudan Investment Management LLP transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Boussard & Gavaudan Investment Management LLP holds 614,939 shares of SAGE stock, worth $5.34 Million. This represents 5.49% of its overall portfolio holdings.
Number of Shares
614,939
Previous 655,662
6.21%
Holding current value
$5.34 Million
Previous $5.98 Million
6.21%
% of portfolio
5.49%
Previous 4.81%
Shares
2 transactions
Others Institutions Holding SAGE
# of Institutions
203Shares Held
50MCall Options Held
790KPut Options Held
440K-
Madison Avenue Partners, LP New York, NY6.08MShares$52.7 Million5.93% of portfolio
-
Black Rock Inc. New York, NY5.22MShares$45.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$28.3 Million0.0% of portfolio
-
Hudson Bay Capital Management LP Greenwich, CT1.95MShares$16.9 Million0.07% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.92MShares$16.6 Million0.01% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $516M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...